Skip to main content

Table 1 Clinical data and laboratory results in the patients of group 1 and controls

From: Increased incidence of precocious and accelerated puberty in females during and after the Italian lockdown for the coronavirus 2019 (COVID-19) pandemic

Variable

 

Group 1

Previous 5 yearsa

P

Population number

37

89

Chronological age at B2 (as referred by parents or family pediatrician)

6.86 ± 0.61

7.22 ± 0.48

p < 0.005

Chronological age at diagnosis (yr)

7.11 ± 0.72

7.53 ± 0.50

p < 0.0005

Time from B2 to diagnosis (months)

3.1 ± 0.9

3.0 ± 0.8

P = NS

Height, SDS

0.84 ± 1.32

0.79 ± 1.44

P = NS

BMI, SDS

0.83 ± 0.91

0.68 ± 0.88

P = NS

Tanner stage at diagnosis (percentage)

 II

43.8

55.5

 

 III

53,1

38.8

p < 0.05

 IV

3.1

5.4

 

 V

 

Bone age (yr)

9.40 ± 1.10

9.60 ± 1.20

p = NS

Bone age minus chronological age (yr)

2.29 ± 0.38

2.07 ± 0.70

P = NS

Basal LH, IU/L

1.2 ± 0.7

0.8 ± 0.6

p < 0.005

Basal FHS, IU/L

1.9 ± 1.7

2.2 ± 1.3

p = NS

Peak LH at GnRH stimulation, IU/L

11.9 ± 4.2

9.4 ± 4.0

p < 0.005

Basal estradiol (females only), pmol/L

129.9 ± 18.7

117.6 ± 19.2

p < 0.005

Uterine length, cm

4.42 ± 0.43

3.99 ± 0.47

p < 0.0005

Ovarian volume, cm3

3.32 ± 0.42

2.83 ± 0.46

p < 0.0005

Electronic device use (h)

3.9 ± 1.5

  1. a= mean/yr. BA bone age, CA chronological age, SDS standard deviation score, BMI body mass index, LH luteinizing hormone, FSH follicle-stimulating hormone, GnRH gonadotropin releasing hormone test